🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Once daily CAB tablet + RPV tablet

Found 13 matching trials

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

PHASE4

The goal of this clinical study is to learn how safe it is to switch to an ...

Status

Completed

Location

Franco Felizarta, MD

Start Date

2023-12-13

Trial ID

NCT06104306

Treatments Being Tested

B/F/TAF

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

PHASE3

This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLA...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2017-10-27

Trial ID

NCT03299049

Treatments Being Tested

Cabotegravir Tablets Rilpivirine Tablets Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

PHASE3

Chronic human immunodeficiency virus (HIV) infection in adults continues to...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-07-08

Trial ID

NCT04001803

Treatments Being Tested

CAB LA+RPV LA

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

PHASE3

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is bein...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-28

Trial ID

NCT02951052

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)2 NRTIs plus an INI, NNRTI, or PI

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

PHASE3

The purpose of this study was to compare the efficacy, safety, and durabili...

Status

Active Not Recruiting

Location

Alabama CRS

Start Date

2019-03-28

Trial ID

NCT03635788

Treatments Being Tested

Standard of Care (SOC) Oral ART Oral RPV Oral CAB RPV-LA Loading Dose CAB-LA Loading Dose RPV-LA Maintenance Dose CAB-LA Maintenance Dose

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

PHASE3

This is a multicentre study carried out in participants living with human i...

Status

Completed

Location

GSK Investigational Site

Start Date

2023-07-06

Trial ID

NCT05917509

Treatments Being Tested

DTG/3TC Cabotegravir (CAB) LA Rilpivirine (RPV) LA

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

PHASE3

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted t...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-27

Trial ID

NCT02938520

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)ABC/DTG/3TC STR - Tablet DTG Tablet

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

PHASE3

This study is designed to assess the antiviral activity and safety of a two...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-11-09

Trial ID

NCT04542070

Treatments Being Tested

Cabotegravir Tablets Cabotegravir Injectable Suspension (CAB LA)Rilpivirine Tablets Rilpivirine Injectable Suspension (RPV LA)BIKTARVY Tablets (BIK)

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

PHASE3

The overall objective of the CAB LA + RPV LA clinical development program i...

Status

Completed

Location

GSK Investigational Site

Start Date

2020-09-28

Trial ID

NCT04399551

Treatments Being Tested

CAB OLI CAB LA RPV OLI RPV LA Continuous Quality Improvement (CQI) calls

Previous Next